SMS Pharmaceuticals532815RPT disclosure
Loan agreement with subsidiary for unsecured loan of up to Rs. 50 Crores
SMS Pharmaceuticals has entered a loan agreement to lend up to Rs. 50 Crores to its subsidiary SMS Peptides Private Limited as an unsecured loan for the subsidiary's business.
By ScoutQuest · · 2 min read
99.99%Company's stake in SMS Peptides Private Limited
- Loan Amount
- up to an aggregate amount not exceeding Rs. 50 Crores
- Stake in Subsidiary
- 99.99% stake in SMS Peptides Private Limited
- Loan Outstanding
- Nil
What was announced
- SMS Pharmaceuticals Limited (the lender) has entered into a Loan Agreement with SMS Peptides Private Limited (the borrower), a subsidiary of the company.
- The agreement was executed on 30th October, 2026.
- The loan is meant to fund the subsidiary's business purpose.
Size and nature of the loan
- The loan is unsecured.
- The size is up to an aggregate amount not exceeding Rs. 50 Crores, to be drawn in one or more tranches.
- The amount of loan outstanding as on the date of this disclosure is Nil.
Who is the borrower
- SMS Peptides Private Limited is a subsidiary of SMS Pharmaceuticals, and the company holds a 99.99% stake in it as on date.
- The two entities have common directors, and the transaction is a related party transaction.
- The company states the transaction is done at arm's length.
Other terms flagged in the disclosure
- The agreement carries no special rights such as a right to appoint directors, a first right to subscribe to shares, or a right to restrict changes in capital structure.
- No nominee-related or potential conflict of interest disclosures were listed separately.
What a reader can take away
- This is an intra-group funding arrangement: the listed company is extending up to Rs. 50 Crores of unsecured credit to a subsidiary it almost wholly owns, rather than the subsidiary raising funds from outside lenders.
- Because the borrower is a related party, the update records the arm's length position and the company's 99.99% shareholding, which are the points investors typically track in such transactions.
- Since the loan is unsecured and the outstanding is Nil on the disclosure date, the figures that matter going forward are how much of the Rs. 50 Crores is actually drawn and on what terms it is repaid.
Also from SMS Pharmaceuticals
Board meeting on 4 November 2026 to consider Q2 and half-year results
28 Oct 2026
More numbers
- Size of loan agreementRs. 50 Crores
- Company's stake in SMS Peptides Private Limited99.99%
- Amount of loan outstanding as on date of disclosureNil
Source: BSE · 30 Oct 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.